CLINICAL TRIALS PROFILE FOR MILNACIPRAN HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for MILNACIPRAN HYDROCHLORIDE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00098124 ↗ | Study of Milnacipran for the Treatment of Fibromyalgia | Completed | Forest Laboratories | Phase 3 | 2004-11-01 | Antidepressants of all varieties represent a common form of therapy for many chronic states including fibromyalgia. The majority of antidepressants increase the levels of serotonin or norepinephrine in the central nervous system. Milnacipran is a dual norepinephrine and serotonin reuptake inhibitor and may be effective in the treatment of fibromyalgia. |
NCT00225511 ↗ | Study Evaluating Effexor XR for Major Depression. | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 3 | 2004-06-01 | Study Evaluating Effexor XR for Major Depression. |
NCT00314249 ↗ | Study of Milnacipran for the Treatment of Fibromyalgia | Completed | Cypress Bioscience, Inc. | Phase 3 | 2006-04-01 | The purpose of this study was to demonstrate the efficacy and safety of milnacipran at a dosage of 100 mg/day in the treatment of the fibromyalgia syndrome or the pain associate with fibromyalgia. |
NCT00314249 ↗ | Study of Milnacipran for the Treatment of Fibromyalgia | Completed | Forest Laboratories | Phase 3 | 2006-04-01 | The purpose of this study was to demonstrate the efficacy and safety of milnacipran at a dosage of 100 mg/day in the treatment of the fibromyalgia syndrome or the pain associate with fibromyalgia. |
NCT00436033 ↗ | A Multicentre Trial to Determine the Efficacy and Safety of Milnacipran in the Treatment of Fibromyalgia Syndrome | Completed | Pierre Fabre Medicament | Phase 3 | 2006-02-01 | Investigation of efficacy and safety of treatment with milnacipran in the treatment of fibromyalgia syndrome. |
NCT00606203 ↗ | Dose Milnacipran Prevent Depressive Symptoms in Patients With Acute Stroke? | Unknown status | Chang Gung Memorial Hospital | N/A | 2007-09-01 | Depression is one of the important psychiatric sequelae after stroke. The prevalence of post stroke depression (PSD) is approximately 20-40%. Depression comorbid with stroke has been found to be associated with increased disability, cognitive function decline, poorer rehabilitation outcome and higher mortality rate.We are going to conduct a trial of prevention of psot stroke depression by prescribing milnacipran in advance. |
NCT00618956 ↗ | A Study Of Milnacipran In Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure Monitoring | Completed | Cypress Bioscience, Inc. | Phase 3 | 2007-10-01 | The study is designed to accurately assess any changes in blood pressure and pulse at 100 and 200 mg daily dose of milnacipran in patients with fibromyalgia syndrome. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for MILNACIPRAN HYDROCHLORIDE
Condition Name
Clinical Trial Locations for MILNACIPRAN HYDROCHLORIDE
Trials by Country
Clinical Trial Progress for MILNACIPRAN HYDROCHLORIDE
Clinical Trial Phase
Clinical Trial Sponsors for MILNACIPRAN HYDROCHLORIDE
Sponsor Name